The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Effects of Tolterodine, Trospium Chloride, and Oxybutynin on the Central Nervous System
Abstract
Antimuscarinic compounds are increasingly used to treat the symptoms of overactive bladder; however, their use is often restricted by peripheral adverse effects (AEs). On the other hand, data regarding their influence on the central nervous system (CNS) are limited. This randomized, single‐blind, parallel‐group quantitative‐topographical EEG (qEEG) study of clinical phase I investigates the potential CNS adverse effects of the three antimuscarinic drugs—tolterodine, oxybutynin, and trospium chloride—in comparison to placebo. Overall, 4 × 16 (total 64) young, healthy male volunteers were included in the study. The subjects were given either placebo or the clinically recommended daily doses of the drugs dispensed in three doses on a single day (tolterodine 2 mg bid and once placebo, total 4 mg/d; oxybutynin 5 mg tid, total 15 mg/d; and trospium chloride 15 mg tid, total 45 mg/d). The qEEG was recorded prior to and up to 4 hours after each intake of the trial medication (a total of 10 qEEG sessions) under three different conditions: at rest with eyes open, eyes closed, and under mental demand. The drug tolerability was subjectively evaluated by the volunteer and the investigator. In comparison to placebo (10% confidence interval), tolterodine and trospium chloride did not induce changes of the qEEG power in five of the six frequency bands (i.e., delta, alpha1, alpha2, beta1, and beta2). Isolated power decreases were only observed in the theta frequency band. In contrast, oxybutynin caused significant power reductions in four frequency bands (theta, alpha1, alpha2, and beta1; p < 0.01). The subjectively evaluated drug tolerability was comparable between all treatment groups, although differences in the AE occurrence existed, with the AE frequency being higher in the oxybutynin group. The results of this study support the findings that oxybutynin as a tertiary amine crosses the blood‐brain barrier, causing significant qEEG activity changes and more pronounced central adverse effects. Although tolterodine is also a tertiary amine, it shows limited effects on qEEG activity (i.e., slight theta power reductions), comparable to the effects of trospium chloride, a quarternary amine, which barely crosses the blood‐brain barrier. The minimal qEEG changes observed with tolterodine and trospium chloride reflect most probably a rebound message from the peripheral target organs. Prescription of oxybutynin thus implicates a higher risk of CNS side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Goodman and Gilman's The Pharmacological Basis of Therapeutics
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-2-175_2 · Cited by 1,224
Explicit Criteria for Determining Potentially Inappropriate Medication Use by the Elderly: An Update
Beers, M. H. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440350031003 · Cited by 1,059
A neurologic basis for the overactive bladder
de Groat, W. C. (1997) · Urology · doi:10.1016/s0090-4295(97)00587-6 · Cited by 596
Sachs, L. (1992) · Springer eBooks · doi:10.1007/978-3-662-05747-6 · Cited by 482
Definition of overactive bladder and epidemiology of urinary incontinence
Hampel, C., Wienhold, D., Benken, N., Eggersmann, C., & Thüroff, J. W. (1997) · Urology · doi:10.1016/s0090-4295(97)00578-5 · Cited by 375
Katz, I. R., Sands, L. P., Bilker, W., DiFilippo, S., Boyce, A., & D'Angelo, K. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb01006.x · Cited by 256
Locus coeruleus neurons and sympathetic nerves: Activation by visceral afferents
Elam, M., Thorén, P., & Svensson, T. H. (1986) · Brain Research · doi:10.1016/0006-8993(86)90964-9 · Cited by 203
The patient with an overactive bladder—Symptoms and quality-of-life issues
Jackson, S. (1997) · Urology · doi:10.1016/s0090-4295(97)00580-3 · Cited by 149
Lechner, S. M., Curtis, A. L., Brons, R., & Valentino, R. J. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00116-9 · Cited by 137
Pontine regulation of pelvic viscera: pharmacological target for pelvic visceral dysfunctions
Valentino, R. J., Miselis, R. R., & Pavcovich, L. A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01332-2 · Cited by 135
Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers
Pietzko, A., Dimpfel, W., Schwantes, U., & Topfmeier, P. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00191165 · Cited by 114
Self-citationThe central control of micturition and continence: implications for urology
Blok, B. F. M., & Holstege, G. (1999) · British Journal of Urology · doi:10.1046/j.1464-410x.83.s2.2.x · Cited by 103
Page, M. E., Akaoka, H., Aston‐Jones, G., & Valentino, R. J. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90295-d · Cited by 92
Treatment of overactive bladder: other drug mechanisms
Andersson, K.-E. (2000) · Urology · doi:10.1016/s0090-4295(99)00495-1 · Cited by 91
Reflection of Mental Exercise in the Dynamic Quantitative Topographical EEG
Schober, F., Schellenberg, R., & Dimpfel, W. (2008) · Neuropsychobiology · doi:10.1159/000119179 · Cited by 52
Self-citationM1 muscarinic antagonists interact with σ recognition sites
Hudkins, R. L., & DeHaven‐Hudkins, D. L. (1991) · Life Sciences · doi:10.1016/0024-3205(91)90135-x · Cited by 51
IPEG Guideline on Statistical Design and Analysis for Pharmacodynamic Trials
Ferber, G., Abt, K., Fichte, K., & Luthringer, R. (1999) · Neuropsychobiology · doi:10.1159/000026567 · Cited by 43
Planning controlled clinical trials on the basis of descriptive data analysis
Abt, K. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100513 · Cited by 26
Cited by
Antimuscarinics for treatment of overactive bladder
Andersson, K.-E. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00622-7 · Cited by 414
Management of Overactive Bladder
Ouslander, J. G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032662 · Cited by 411
Kay, G. G., & Ebinger, U. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01849.x · Cited by 141
Bladder, Bowel, and Sexual Dysfunction in Parkinson's Disease
Sakakibara, R., Kishi, M., Ogawa, E., Tateno, F., Uchiyama, T., Yamamoto, T., & Yamanishi, T. (2011) · Parkinson's Disease · doi:10.4061/2011/924605 · Cited by 118
Use of CNS medications and cognitive decline in the aged: a longitudinal population-based study
Puustinen, J., Nurminen, J., Löppönen, M., Vahlberg, T., Isoaho, R., Räihä, I., & Kivelä, S.-L. (2011) · BMC Geriatrics · doi:10.1186/1471-2318-11-70 · Cited by 51
“The blood-brain barrier permeability of different anticholinergic medications may differ depending on molecules [28], age [29] or disease states [30], which might explain why the risk of cognitive deterioration was detected only among men.”
Background
Metadata
- Authors
- Todorova, A., Vonderheid‐Guth, B., & Dimpfel, W.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2001-06
- Volume
- 41
- Issue
- 6
- Pages
- 636-644
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2026522667
- Cited by
- 271
- References
- 19
- FWCI
- 13.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.